NCT00871780 - A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions

DRUG

BG00002 (natalizumab)

Trial Locations (15)

Biogen Idec Investigative Site, Liège

Biogen Idec Investigative Site, Puebla City

Biogen Idec Investigative Site, Bialystok

Biogen Idec Investigative Site, Bydgoszcz

Biogen Idec Investigative Site, Lodz

Biogen Idec Investigative Site, Poznan

Biogen Idec Investigative Site, Warsaw

Biogen Idec Investigative Site, Bucharest

Biogen Idec Investigative Site, Mures

Biogen Idec Investigative Site, Riyadh

Biogen Idec Investigative Site, Dnipropetrovsk

Biogen Idec Investigative Site, Kharkiv

Biogen Idec Investigative Site, Kyiv

Biogen Idec Investigative Site, Lviv

Biogen Idec Investigative Site, Simferopol